1. Home
  2. YORW vs PRTC Comparison

YORW vs PRTC Comparison

Compare YORW & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo York Water Company (The)

YORW

York Water Company (The)

HOLD

Current Price

$30.20

Market Cap

472.0M

Sector

Utilities

ML Signal

HOLD

Logo PureTech Health plc

PRTC

PureTech Health plc

HOLD

Current Price

$15.39

Market Cap

464.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YORW
PRTC
Founded
1816
2015
Country
United States
United States
Employees
104
N/A
Industry
Water Supply
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
472.0M
464.3M
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
YORW
PRTC
Price
$30.20
$15.39
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
126.0K
3.4K
Earning Date
03-03-2026
04-29-2026
Dividend Yield
2.99%
N/A
EPS Growth
N/A
N/A
EPS
1.39
N/A
Revenue
$77,488,000.00
N/A
Revenue This Year
$11.78
N/A
Revenue Next Year
$4.95
N/A
P/E Ratio
$21.92
$8.09
Revenue Growth
3.37
N/A
52 Week Low
$29.68
$13.30
52 Week High
$36.48
$20.00

Technical Indicators

Market Signals
Indicator
YORW
PRTC
Relative Strength Index (RSI) 35.52 33.39
Support Level $30.02 $14.50
Resistance Level $32.98 $18.10
Average True Range (ATR) 0.68 0.41
MACD -0.08 -0.09
Stochastic Oscillator 20.72 14.29

Price Performance

Historical Comparison
YORW
PRTC

About YORW York Water Company (The)

The York Water Co is an investor-owned water utility company in the United States. The primary business of the company is to impound, purify to meet or exceed safe drinking water standards and distribute water. It also owns and operates three wastewater collection systems and eleven wastewater collection and treatment systems. The company operates within its franchised territory, which covers more than 57 municipalities within four counties in south-central Pennsylvania.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: